Total revenue for the fourth quarter and full year 2025 was approximately $72 million and $277 million, representing an increase of 51% and 55%, respectively, over the corresponding periods in 2024.
MRD revenue for the fourth quarter and full year 2025 was approximately $62 million and $212 million, representing an increase of 54% and 46%, respectively, over the corresponding periods in 2024. Excluding MRD regulatory milestone revenue, MRD revenue for full year 2025 grew 45% over the corresponding period in 2024.
clonoSEQ test volume increased 43% to approximately 30,000 tests in the fourth quarter 2025 compared to the fourth quarter 2024 and ended the year with approximately 105,600 tests delivered, up 39% compared to full year 2024.
Cash, cash equivalents and marketable securities were approximately $227 million as of December 31, 2025.1
"2025 was a pivotal year for Adaptive, marked by accelerating momentum across our MRD business driven by strong growth in clonoSEQ adoption," said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. "As we look ahead to 2026, we are well-positioned to extend our leadership in MRD testing, sustain strong clonoSEQ volume and ASP growth, and further expand MRD profitability."
Adaptive Biotechnologies plans to release its ...
